ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2025
Poor olfaction and risk of heart failure in the Atherosclerosis Risk in Communities Study.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Olfactory dysfunction and increased systemic immune inflammation index in patients with atrial fibrillation.Biomolecules & biomedicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundPoor olfaction may be associated with incident heart failure (HF) in older adults, but empirical evidence is scant.
methodsWe included 5217 participants free of clinical HF and with a smell assessment in 2011-2013 from the Atherosclerosis Risk in Communities Study. Olfaction was measured by the 12-item Sniffin' Sticks odor identification test and defined as good (score 11-12), moderate (9-10), or poor (≤8). Participants were followed until the first HF hospitalization, death, last contact, or December 31, 2020, whichever happened first. We estimated adjusted risk ratios (aRR) for associations of olfaction with incident HF and its subtypes, and cross-sectional associations of olfaction with subclinical HF markers, including N-terminal pro-B-type natriuretic peptides (NT-proBNP), high-sensitive cardiac troponin T (hs-cTnT), and echocardiogram-defined structural heart disease.
resultsDuring a median 8.4-year follow-up, we identified 622 incident HF, including 212 with reduced ejection fraction (HFrEF) and 250 with preserved EF (HFpEF). Comparing poor with good olfaction, the aRR of HF was 1.24 (95% confidence interval (CI): 1.03,1.51) at year 8. Moderate olfaction showed a similar association pattern with HF risk, with the corresponding aRR of 1.23 (95% CI, 1.00-1.50). Poor olfaction appeared to have an evident association with HFrEF but not with HFpEF. Poor olfaction was associated with higher median levels of NT-proBNP and hs-cTnT, and higher odds of having structural heart disease than good olfaction.
conclusionsIn older adults, poor olfaction identified by a single smell test was associated with a modestly higher risk of HF, especially HFrEF, and with known subclinical HF biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.